<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04219059</url>
  </required_header>
  <id_info>
    <org_study_id>ProTex</org_study_id>
    <nct_id>NCT04219059</nct_id>
  </id_info>
  <brief_title>MR Radiomic Features in Prostate Cancer</brief_title>
  <official_title>MR Radiomic Features in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CNR IBFM (Istituto di Bioimmagini e Fisiologia Molecolare), Segrate, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A combination of correct interpretation of imaging and biopsy has given promising results in
      terms of detecting clinically significant cancer at radical prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quantitative approaches to medical image analysis have been developed in recent years with
      the aim to overcome the limitation of qualitative image interpretation, and provide
      biomarkers for disease characterization. In particular, the new paradigm, &quot;radiomics&quot;, is
      emerging as the high-throughput extraction of quantitative features from imaging which can
      aid in characterizing phenotype as in vivo expression of tumoral genotype. The goal of
      radiomics is to extract accurate and reliable quantitative biomarkers which enhance
      diagnostic confidence in oncology. A combination of correct interpretation of imaging and
      biopsy has given promising results in terms of detecting clinically significant cancer at
      radical prostatectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">September 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of surrogate bioimaging markers of histological characteristics in MR images</measure>
    <time_frame>0-2 years</time_frame>
    <description>Segment tumor volumes on the ADC map and extract different imaging features</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extract radiomic features from MRI</measure>
    <time_frame>0-2 years</time_frame>
    <description>Evaluate if radiomic features on primitive prostate lesions can describe lymph node involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extract radiomic features from MRI</measure>
    <time_frame>0-2 years</time_frame>
    <description>Evaluate if radiomic features on primitive prostate lesions can describe disease extension.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        200 male patients who have a pre-intervention prostate MRI with contrast agent from
        December 2015 to August 30, 2019 and biopsy proven Pca diagnosis, followed by radical
        prostatectomy will be evaluated.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  In house MRI with contrast medium

          -  PCa (prostate cancer) biopsy proven diagnosis

          -  In house radical prostatectomy

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  MRI without contrast medium

          -  Radical prostatectomy executed not in Institution
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Steidler, PhD</last_name>
      <phone>+390226436111</phone>
      <email>steidler.stephanie@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Giulia Cristel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Damascelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Francesco De Cobelli</investigator_full_name>
    <investigator_title>Head, Radiology Department</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>prostate</keyword>
  <keyword>radiomics</keyword>
  <keyword>MRI</keyword>
  <keyword>prognostic factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

